Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment
CONCLUSIONS: According to our results, everolimus accelerates tumor mass reduction, but not amount of mass regression in the long term. Everolimus may be considered for treatment of rhabdomyomas which cause hemodynamic compromise or life-threatening arrhythmias before surgical intervention.PMID:37395967 | DOI:10.24953/turkjped.2022.922 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - July 3, 2023 Category: Pediatrics Authors: Sayg ın Yıldırım Ebru Aypar Bur ça Aydın Canan Aky üz Hayrettin Hakan Aykan İlker Ertuğrul Tevfik Karag öz Dursun Alehan Source Type: research
Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment
CONCLUSIONS: According to our results, everolimus accelerates tumor mass reduction, but not amount of mass regression in the long term. Everolimus may be considered for treatment of rhabdomyomas which cause hemodynamic compromise or life-threatening arrhythmias before surgical intervention.PMID:37395967 | DOI:10.24953/turkjped.2022.922 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - July 3, 2023 Category: Pediatrics Authors: Sayg ın Yıldırım Ebru Aypar Bur ça Aydın Canan Aky üz Hayrettin Hakan Aykan İlker Ertuğrul Tevfik Karag öz Dursun Alehan Source Type: research
Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment
CONCLUSIONS: According to our results, everolimus accelerates tumor mass reduction, but not amount of mass regression in the long term. Everolimus may be considered for treatment of rhabdomyomas which cause hemodynamic compromise or life-threatening arrhythmias before surgical intervention.PMID:37395967 | DOI:10.24953/turkjped.2022.922 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - July 3, 2023 Category: Pediatrics Authors: Sayg ın Yıldırım Ebru Aypar Bur ça Aydın Canan Aky üz Hayrettin Hakan Aykan İlker Ertuğrul Tevfik Karag öz Dursun Alehan Source Type: research
Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment
CONCLUSIONS: According to our results, everolimus accelerates tumor mass reduction, but not amount of mass regression in the long term. Everolimus may be considered for treatment of rhabdomyomas which cause hemodynamic compromise or life-threatening arrhythmias before surgical intervention.PMID:37395967 | DOI:10.24953/turkjped.2022.922 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - July 3, 2023 Category: Pediatrics Authors: Sayg ın Yıldırım Ebru Aypar Bur ça Aydın Canan Aky üz Hayrettin Hakan Aykan İlker Ertuğrul Tevfik Karag öz Dursun Alehan Source Type: research
Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment
CONCLUSIONS: According to our results, everolimus accelerates tumor mass reduction, but not amount of mass regression in the long term. Everolimus may be considered for treatment of rhabdomyomas which cause hemodynamic compromise or life-threatening arrhythmias before surgical intervention.PMID:37395967 | DOI:10.24953/turkjped.2022.922 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - July 3, 2023 Category: Pediatrics Authors: Sayg ın Yıldırım Ebru Aypar Bur ça Aydın Canan Aky üz Hayrettin Hakan Aykan İlker Ertuğrul Tevfik Karag öz Dursun Alehan Source Type: research
Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment
CONCLUSIONS: According to our results, everolimus accelerates tumor mass reduction, but not amount of mass regression in the long term. Everolimus may be considered for treatment of rhabdomyomas which cause hemodynamic compromise or life-threatening arrhythmias before surgical intervention.PMID:37395967 | DOI:10.24953/turkjped.2022.922 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - July 3, 2023 Category: Pediatrics Authors: Sayg ın Yıldırım Ebru Aypar Bur ça Aydın Canan Aky üz Hayrettin Hakan Aykan İlker Ertuğrul Tevfik Karag öz Dursun Alehan Source Type: research
Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment
CONCLUSIONS: According to our results, everolimus accelerates tumor mass reduction, but not amount of mass regression in the long term. Everolimus may be considered for treatment of rhabdomyomas which cause hemodynamic compromise or life-threatening arrhythmias before surgical intervention.PMID:37395967 | DOI:10.24953/turkjped.2022.922 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - July 3, 2023 Category: Pediatrics Authors: Sayg ın Yıldırım Ebru Aypar Bur ça Aydın Canan Aky üz Hayrettin Hakan Aykan İlker Ertuğrul Tevfik Karag öz Dursun Alehan Source Type: research
Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment
CONCLUSIONS: According to our results, everolimus accelerates tumor mass reduction, but not amount of mass regression in the long term. Everolimus may be considered for treatment of rhabdomyomas which cause hemodynamic compromise or life-threatening arrhythmias before surgical intervention.PMID:37395967 | DOI:10.24953/turkjped.2022.922 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - July 3, 2023 Category: Pediatrics Authors: Sayg ın Yıldırım Ebru Aypar Bur ça Aydın Canan Aky üz Hayrettin Hakan Aykan İlker Ertuğrul Tevfik Karag öz Dursun Alehan Source Type: research
Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment
CONCLUSIONS: According to our results, everolimus accelerates tumor mass reduction, but not amount of mass regression in the long term. Everolimus may be considered for treatment of rhabdomyomas which cause hemodynamic compromise or life-threatening arrhythmias before surgical intervention.PMID:37395967 | DOI:10.24953/turkjped.2022.922 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - July 3, 2023 Category: Pediatrics Authors: Sayg ın Yıldırım Ebru Aypar Bur ça Aydın Canan Aky üz Hayrettin Hakan Aykan İlker Ertuğrul Tevfik Karag öz Dursun Alehan Source Type: research
Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment
CONCLUSIONS: According to our results, everolimus accelerates tumor mass reduction, but not amount of mass regression in the long term. Everolimus may be considered for treatment of rhabdomyomas which cause hemodynamic compromise or life-threatening arrhythmias before surgical intervention.PMID:37395967 | DOI:10.24953/turkjped.2022.922 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - July 3, 2023 Category: Pediatrics Authors: Sayg ın Yıldırım Ebru Aypar Bur ça Aydın Canan Aky üz Hayrettin Hakan Aykan İlker Ertuğrul Tevfik Karag öz Dursun Alehan Source Type: research
Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment
CONCLUSIONS: According to our results, everolimus accelerates tumor mass reduction, but not amount of mass regression in the long term. Everolimus may be considered for treatment of rhabdomyomas which cause hemodynamic compromise or life-threatening arrhythmias before surgical intervention.PMID:37395967 | DOI:10.24953/turkjped.2022.922 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - July 3, 2023 Category: Pediatrics Authors: Sayg ın Yıldırım Ebru Aypar Bur ça Aydın Canan Aky üz Hayrettin Hakan Aykan İlker Ertuğrul Tevfik Karag öz Dursun Alehan Source Type: research
Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment
CONCLUSIONS: According to our results, everolimus accelerates tumor mass reduction, but not amount of mass regression in the long term. Everolimus may be considered for treatment of rhabdomyomas which cause hemodynamic compromise or life-threatening arrhythmias before surgical intervention.PMID:37395967 | DOI:10.24953/turkjped.2022.922 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - July 3, 2023 Category: Pediatrics Authors: Sayg ın Yıldırım Ebru Aypar Bur ça Aydın Canan Aky üz Hayrettin Hakan Aykan İlker Ertuğrul Tevfik Karag öz Dursun Alehan Source Type: research
Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment
CONCLUSIONS: According to our results, everolimus accelerates tumor mass reduction, but not amount of mass regression in the long term. Everolimus may be considered for treatment of rhabdomyomas which cause hemodynamic compromise or life-threatening arrhythmias before surgical intervention.PMID:37395967 | DOI:10.24953/turkjped.2022.922 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - July 3, 2023 Category: Pediatrics Authors: Sayg ın Yıldırım Ebru Aypar Bur ça Aydın Canan Aky üz Hayrettin Hakan Aykan İlker Ertuğrul Tevfik Karag öz Dursun Alehan Source Type: research
Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment
CONCLUSIONS: According to our results, everolimus accelerates tumor mass reduction, but not amount of mass regression in the long term. Everolimus may be considered for treatment of rhabdomyomas which cause hemodynamic compromise or life-threatening arrhythmias before surgical intervention.PMID:37395967 | DOI:10.24953/turkjped.2022.922 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - July 3, 2023 Category: Pediatrics Authors: Sayg ın Yıldırım Ebru Aypar Bur ça Aydın Canan Aky üz Hayrettin Hakan Aykan İlker Ertuğrul Tevfik Karag öz Dursun Alehan Source Type: research
Primary cardiac sarcomas: A clinicopathologic study in a single institution with 25 years of experience with an emphasis on MDM2 expression and adjuvant therapy for prognosis
ConclusionOur study supports the use of adjuvant treatment in primary cardiac sarcoma, as it was associated with a significantly better overall survival rate. Further consideration of tumor histology may be important in determining the optimal use of adjuvant treatment for different types of sarcomas. Therefore, accurate diagnosis by MDM2 test is important condsidering patient's prognosis and treatment. (Source: Cancer Medicine)
Source: Cancer Medicine - July 3, 2023 Category: Cancer & Oncology Authors: Haeyon Cho,
In ‐Hye Song,
Uiree Jo,
Ji‐Seon Jeong,
Hyun Jung Koo,
Dong Hyun Yang,
Sung‐Ho Jung,
Joon Seon Song,
Kyung‐Ja Cho Tags: RESEARCH ARTICLE Source Type: research
